Benzinga | Apr 26, 2021 07:09AM EDT

Soligenix Highlights Presentation Of HyBryte Expanded Efficacy And Safety Data Presented At American Academy of Dermatology Meeting

Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Ellen Kim, MD, Medical Director, Dermatology Clinic, Perelman Center for Advanced Medicine, Professor of Dermatology at the Hospital of the University of Pennsylvania, and the Lead Principal Investigator for the Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study, delivered a presentation at the American Academy of Dermatology (AAD) Association Virtual Meeting Experience, held April 23-25, 2021. The presentation, which was designated "Top 12 Late-Breaking Research," expanded on data related to the efficacy and safety of HyBryte(tm) (SGX301) in the treatment of cutaneous T-cell lymphoma (CTCL).